Holen Sie sich die Stockscreener-App
177.34
3.50%
-6.44
Handel nachbörslich:
177.34
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$183.78
Offen:
$181.46
24-Stunden-Volumen:
1.34M
Relative Volume:
1.03
Marktkapitalisierung:
$26.03B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
20.14
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
-7.18%
1M Leistung:
-5.70%
6M Leistung:
+14.23%
1J Leistung:
+35.04%
1-Tages-Spanne:
$176.39
$181.98
1-Wochen-Bereich:
$171.37
$191.06
52-Wochen-Spanne:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
177.34 | 26.97B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
935.58 | 852.73B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 587.99B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 380.25B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 311.30B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.76B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - finance.yahoo.com
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen (NASDAQ:BIIB) Target Revision Sparks Nasdaq Futures Focus - Kalkine Media
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
H.C. Wainwright raises Biogen stock price target on Apellis deal By Investing.com - Investing.com India
H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com
BIIB Analyst Rating: HC Wainwright & Co. Raises Price Target to $237 | BIIB Stock News - GuruFocus
Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - IndexBox
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive
Canaccord Genuity Raises Price Target for Biogen (BIIB) to $245 - GuruFocus
Mass. companies close major deals in biotech, media in March - The Business Journals
Biogen Inc (BSP:BIIB34) Stock Price, Trades & News - GuruFocus
Oppenheimer Raises Biogen (BIIB) Price Target to $275, Maintains Outperform Rating | BIIB Stock News - GuruFocus
FDA Approves Higher-Dose Regimen of Nusinersen for Spinal Muscular Atrophy - Pharmacy Times
Biogen’s $5.6bn Apellis Deal Delivers Windfall for Worldwide Healthcare Trust - TipRanks
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion - Investing.com
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion By Investing.com - Investing.com India
Biogen stock is locked into a rising trendline — And $202.41 is the destination - fxstreet.com
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - Pharmaceutical Executive
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - TradingView
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes - BioSpace
Canaccord Genuity Adjusts Biogen PT to $245 From $230, Maintains Buy Rating - MarketScreener
Oppenheimer Adjusts Price Target on Biogen to $275 From $250, Maintains Outperform Rating - MarketScreener
Biogen stock price target raised to $245 by Canaccord on Apellis deal - Investing.com
Wedbush Raises Price Target on Biogen to $191 From $187, Keeps Neutral Rating - marketscreener.com
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - finance.yahoo.com
Apellis Pharmaceuticals to be Acquired by Biogen in Merger - TipRanks
Biogen bolsters immunology offerings with $5.6bn Apellis buy - bioxconomy.com
Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger - finance.yahoo.com
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio - TipRanks
Why Biogen Stock Sank While the Market Soared on Thursday - finance.yahoo.com
Biogen strengthens push into nephrology with $5.6B Apellis deal - biocentury.com
Biogen to acquire Apellis Pharmaceuticals for approximately $5.6bn - MLex
Big Drug Companies Hunting for Deals Are Lowering Their Sights - wsj.com
Biogen Paying $5.6B For Apellis As 4 Firms Advise - Law360
Biogen to buy Apellis (Nasdaq: APLS) for $41 cash plus CVR upside - stocktitan.net
[8-K] BIOGEN INC. Reports Material Event - stocktitan.net
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise - Bloomberg.com
Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on Announcement - GuruFocus
Biogen Snaps Up $5.6 Billion Deal. Why Shares Fell. - Investor's Business Daily
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth ObjectivesSlideshow - Seeking Alpha
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock? - Barchart.com
Biogen's Apellis Deal Addresses Some Revenue Growth Concerns -- Market Talk - Moomoo
Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing (NASDAQ:APLS) - Seeking Alpha
Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's
Guggenheim reiterates Buy on Biogen stock after Apellis deal - Investing.com
Market movers: Apellis Pharmaceutical, Unilever, McCormick, Biogen... - Proactive financial news
Biogen (BIIB.US) Plans to Acquire Apellis (APLS.US) for USD5.6 Billion to Expand Rare Disease Portfolio - AASTOCKS.com
Annexon (ANNX) Gains Attention Amid Pharma Deal Activity - GuruFocus
Biogen (NASDAQ:BIIB) Stock Gap Movement Draws Nasdaq Composite Focus - Kalkine Media
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
1.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):